Yan Degenhardt

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 512 citations · Full text

Medicine, Molecular Biology, Oncology +12

Critical role for Daxx in regulating Mdm2

Jun Tang, Like Qu, Jianke Zhang et al. · Nature Cell Biology · 2006 · 236 citations

Life Sciences, Cell Biology, Molecular Biology +3

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Anastasia Wyce, Yan Degenhardt, Yuchen Bai et al. · Oncotarget · 2013 · 177 citations · Full text

Medicine, Molecular Biology, Oncology +17

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb^®, GW572016) in an expanded panel of human normal and tumour cell lines

David W. Rusnak, Krystal J. Alligood, Robert J. Mullin et al. · Cell Proliferation · 2007 · 174 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

David Olmos, Douglas S. Barker, Rohini Sharma et al. · Clinical Cancer Research · 2011 · 168 citations · Full text

Medicine, Oncology, Pharmacology +16